Coronavirus Notebook: New Therapeutic Approaches, Fair Access To Dexamethasone, & Patent Help From The EPO

 
• By Ian Schofield
  
Generate a summary of this article
Listen to this article
Beta

With COVID-19 cases about to top 12 million worldwide, efforts are continuing to identify the most promising drug candidates and to ensure that the rising star dexamethasone is made available to all.

Covid19_Lungs_Vial
Research continues into mitigating respiratory problems in COVID-19 patients • Source: Shutterstock

One of the few products that have been shown to reduce mortality in critically ill COVID-19 patients is dexamethasone, a widely available generic steroid that is already on the World Health Organization’s Model List of Essential Medicines for use in reducing inflammation. This very cheap drug could be of particular benefit to coronavirus patients in low- and middle-income countries (LMICs), but it will be important to ensure they have access to the product given that it will be in high demand in better resourced parts of the world.

For this reason Unitaid and Wellcome have joined up with partners in the Access to COVID-19 Tools Accelerator (ACT-A) to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography